AKBA$1.1355

Akebia Therapeutics Inc

PharmaceuticalsVerified

Akebia Therapeutics Inc (AKBA.O) is currently classified as Pharmaceuticals within Pharmaceuticals (Healthcare). Classification confidence: 0.92 (verified market data). Capital structure on the latest snapshot: total assets 376,565,000 USD, total equity 32,610,000, short-term debt 0, long-term debt 193,570,000. Net cash position is approximately -8,726,000 USD. Self-calculated market cap is 303,122,549 USD (market_price × shares_outstanding_diluted). Profitability profile: revenue 236,196,000, gross profit 195,838,000, operating income 23,499,000, net income -5,345,000. Return on equity ~-16.4%. Return on assets ~-1.4%. Operating-cash-flow to net-income ratio is -12.72. Risk profile from automated assessment: liquidity risk medium, dilution risk low. Flags: Net cash is negative after subtracting total debt..

30-day price · AKBA(missing data)

No daily-bar history available from current data sources. Alternate source pending.

Profile

CompanyAkebia Therapeutics Inc

TickerAKBA.O

SectorHealthcare

BusinessPharmaceuticals & Medical Research

Industry groupPharmaceuticals & Medical Research

IndustryPharmaceuticals

AI analysis

Business. Akebia Therapeutics Inc is classified under Healthcare / Pharmaceuticals and appears not currently profitable on the latest normalized snapshot.

Classification. Classification confidence is 0.92 based on verified market data; matched terms: Pharmaceuticals, Pharmaceuticals & Medical Research, Healthcare.

Key takeaways

Return on equity is about -16.4%.
Debt to equity is about 5.94x.
Analyst estimate: Mean price target = 4.40 USD
Analyst estimate: Median price target = 4.00 USD

Financial snapshot

PeriodHA-latest

CurrencyUSD

Revenue$236.2M

Gross profit$195.8M

Operating income$23.5M

Net income-$5.3M

R&D—

SG&A—

D&A—

SBC—

Operating cash flow$68.0M

CapEx-$8.1M

Free cash flow-$12.2M

Total assets$376.6M

Total liabilities$344.0M

Total equity$32.6M

Cash & equivalents$184.8M

Long-term debt$193.6M

Valuation

Market price$1.13

Market cap$303.1M

Enterprise value$311.8M

P/E—

Reported non-GAAP P/E—

EV/Revenue1.3

EV/Op income13.3

EV/OCF4.6

P/B9.3

P/Tangible book9.3

Tangible book$32.6M

Net cash-$8.7M

Current ratio1.6

Debt/Equity5.9

ROA-1.4%

ROE-16.4%

Cash conversion-12.7%

CapEx/Revenue-3.4%

SBC/Revenue—

Asset intensity—

Dilution ratio0.0%

Risk assessment

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Industry benchmarks

Activity: Pharmaceuticals · cohort 779 companies

MetricAKBAActivity

Op margin9.9%7.7% medp25 -2.4% · p75 15.5%above median

Net margin-2.3%5.9% medp25 -3.8% · p75 12.8%below median

Gross margin82.9%45.5% medp25 31.1% · p75 62.9%top quartile

R&D / revenue—529.2% medp25 465.2% · p75 593.2%

CapEx / revenue-3.4%-7.0% medp25 -14.9% · p75 -3.2%above median

Debt / equity594.0%25.0% medp25 3.8% · p75 63.3%top quartile

Observations

IR observations

Mean price target4.40 USD

Median price target4.00 USD

High price target6.00 USD

Low price target3.00 USD

Mean recommendation1.40 (1=strong buy, 5=strong sell)

Strong-buy count3.00

Buy count2.00

Hold count0.00

Sell count0.00

Strong-sell count0.00

Mean EPS estimate-0.08 USD

Last actual EPS-0.02 USD

Source data

Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.

Company fundamentalsperiod financials

no public URL

2026-05-16 13:44 UTC#09b979f8

Market quoteclose USD 1.18 · shares 0.27B diluted

no public URL

2026-05-16 13:46 UTC#08989fce

Source: analysis-pipeline (hybrid)Generated: 2026-05-27 07:35 UTCJob: e2febffa